logo

For the Inventor, By the Inventor

Burlington, Canada

Stephen E Horne

This inventor holds 24 USPTO granted patents and 2 published patent applications, primarily in Pharmaceutical Chemistry. Top assignees: Apotex Pharmachem Inc., Brantford Chemicals Inc., Syntex (u.s.a.) Inc.. Active years: 1997-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen E Horne. Retrieved from https://idiyas.com/inventor/stephen-e-horne

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 41.7

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Brantford, CA (2010)
  • Burlington, CA (1997 - 2013)

Company Filing History:

goldMedal12 out of 50 
 
Apotex Pharmachem Inc.
 patents
silverMedal7 out of 23 
 
Brantford Chemicals Inc.
 patents
bronzeMedal4 out of 932 
 
Syntex (u.s.a.) Inc.
 patents
4. 1 out of 12 
 
Acic (Canada) Inc.
 patents

Years Active: 1997-2013

Loading Chart...
Areas of Expertise:
Esomeprazole
Atorvastatin
Matrix Metalloprotease Inhibitors
Fluconazole
Cis-2-Methylspiro
Chiral Compounds
Antiviral Nucleosides
Solid Phase Reactions
Polypeptides
Purification Processes
Acid Addition Salts
24 patents (USPTO):Explore Patents
1. 8563733 - Process for the preparation of esomeprazole and salts thereof (2013-10-22),
2. 8471011 - Preparation of acid addition salts of amine bases by solid phase—gas phase reactions (2013-06-25),
3. 8143400 - Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3')quiniclidine hydrochloride (2012-03-27),
4. 8080663 - Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3')quiniclidine (2011-12-20),
5. 7939662 - Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same (2011-05-10),
6. 7851619 - Process for the preparation and purification of eplerenone (2010-12-14),
7. 7786309 - Process for the preparation of esomeprazole and salts thereof (2010-08-31),
8. 7767843 - Process for the preparation of phenylcarbamates (2010-08-03),
9. 7615647 - Process for producing atorvastatin hemicalcium (2009-11-10),
10. 7193090 - Preparation of atorvastatin (2007-03-20),
11. 7087611 - Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride) (2006-08-08),
12. 7049399 - Process for the preparation of polypeptide 1 (2006-05-23),
13. 6642384 - Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives (2003-11-04),
14. 6593475 - Preparation of derivative of 3-sulfonamido-4-phenylaminopyridine (2003-07-15),
15. 6579890 - Matrix metalloprotease inhibitors (2003-06-17),

Title: Stephen E Horne - Innovator from Burlington, CA

Introduction: Stephen E Horne is a renowned inventor based in Burlington, CA, known for his groundbreaking contributions to various industries.

Latest Patents: Stephen E Horne holds several patents in the fields of technology, healthcare, and environmental sustainability, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Stephen E Horne has worked with leading companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Stephen E Horne has collaborated with top researchers, engineers, and scientists to bring his inventions to life, fostering a culture of innovation and creativity.

Conclusion: Stephen E Horne's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in Burlington, CA, and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…